In a review of the polycythemia vera (PV) landscape, researchers outline new perspectives in the diagnosis, prognosis, and treatment of the disease.
The landscape of PV of polycythemia vera (PV) is evolving, with new perspectives in the diagnosis, prognosis, and treatment of the disease. In a recent review appearing in International Journal of Molecular Sciences, researchers outline the latest in PV.
Diagnosis
Since the World Health Organization (WHO) made significant changes to the PV diagnostic criteria in 2016, there have been a higher number of PV diagnoses made among cases that would have previously been diagnosed as myeloproliferative neoplasms (MPN), largely driven by the recognition of the so-called “masked PV,” which is associated with worse outcomes.
A second factor behind the increase was the inclusion of bone marrow (BM) biopsy, for 2 reasons: it can aid in distinguishing between PV and JAK2-positive essential thrombocythemia (ET), and it allows for assessing BM fibrosis as a grade diagnosis allowing for identification of a more aggressive disease.
Among other changes made by WHO in 2016 was the lowering of diagnostic thresholds for hemoglobin and hematocrit (Hct), which were lowered to 16.5 g/dL and 49% for men, and 16 g/dL and 48% for women, respectively. The researchers also highlighted the removal of the endogenous erythroid colony formation “in vitro” as a minor diagnostic criterion.
Prognosis
With thrombotic events being the main cause of morbidity and mortality for patients with PV, the researchers described the emphasis placed on cardiovascular (CV) risk stratification at diagnosis. Currently, patients are typically stratified in 2 categories based on thrombotic risk: a low-risk group of patients aged under 60 years with no previous thromboses and a high-risk group of patients aged older than 60 years and/or with previous thrombotic complications.
It’s been proposed that CV risk factors—hypertension, smoking habits, and leukocytosis—be accounted for in the risk scoring system, as they contribute to the overall risk of thrombosis. Other possible CV risk factors, including red cell distribution width, have also emerged.
Treatment
Historically, management of PV has focused on minimizing the risk of thrombo-hemorrhagic complications, with frontline therapy typically consisting of a combination of phlebotomy to decrease Hct to <45% and low-dose aspirin.
The management of white blood cell (WBC) and platelet counts also represent important treatment goals, as patients with WBC counts ≥ 11 × 109/L versus <7 × 109/L have been shown to have a 4-time greater risk of major thromboses.
With a goal of achieving Hct target levels and normalizing platelet counts, many patients require a cytoreductive treatment, which includes several conventional therapies:
There are also several new drugs under development, including givinostat—a histone daecetylases inhibitor—and idasanutlin—a second-generation oral nutlin.
“While new drugs have recently entered the clinical arena with the promise to improve overall patients’ management, the evidence of a disease-modifying treatment is largely missing,” explained the researchers. “There are several aspects concerning PV, however, that once clarified, might represent significant steps forward for a more adequate and successful treatment strategy, such as a better use of mutational genetics to improve the thrombotic risk stratification of PV patients and a more precise definition of response/safety criteria, which should guide the physician in selecting the most appropriate drug.”
Reference
Iurlo A, Cattaneo D, Bucelli C, Baldini L. New perspectives on polycythemia vera: from diagnosis to therapy. Int J Mol Sci. Published online August 13, 2020. doi:10.3390/ijms21165805.
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Contributor: How Patients and Caregivers Can Be a Catalyst for Rare Disease Innovation
November 5th 2023Patient input and experiences play a crucial role in advancing rare disease research and therapy development, as they help define the disease, inform clinical trial design, and influence regulators and payers' decisions, ultimately serving as catalysts for innovation in the field.
Read More